Get started
Author

Laetitia Da Meda

Observed names: L. Da Meda, L. Da-Meda, L. da Meda, Laetitia Da-Meda, Laetitia Meda, Laetitia da Meda
Institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Génomes, biologie cellulaire et thérapeutiques, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Institut de recherche Saint-Louis
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Génomes, biologie cellulaire et thérapeutiques, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Institut de recherche Saint-Louis, Centre d'Investigation Clinique Saint-Louis
ORCID: 0000-0003-2988-6792
Observed ORCID: 0000-0003-2988-6792
OpenAlex ID: A5063900957
Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review
2017 · Marie-Léa Gauci, Pauline Laly, et al. · Cancer Immunology Immunotherapy · 136
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
2022 · Julie Delyon, Lucie Biard, et al. · The Lancet Oncology · 72
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab
2017 · Marie-Léa Gauci, Barouyr Baroudjian, et al. · Seminars in Arthritis and Rheumatism · 50
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
2018 · Marie-Léa Gauci, Philippe Boudou, et al. · Cancer Immunology Immunotherapy · 36
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
2021 · Nader Yatim, Jeremy Boussier, et al. · Science Advances · 34
PDF
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
2023 · Alison M. Weppler, Laetitia Da Meda, et al. · European Journal of Cancer · 26
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
2021 · Jessica Beaziz, Maxime Battistella, et al. · Cancers · 23
PDF
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
2021 · Baptiste Louveau, Matthieu Resche-Rigon, et al. · Clinical Cancer Research · 21
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
2020 · Julie Delyon, Raphael Porcher, et al. · Journal of Investigative Dermatology · 19
PDF
Focal necrotizing myopathy with ‘dropped-head syndrome’ induced by cobimetinib in metastatic melanoma
2017 · Marie-Léa Gauci, Pauline Laly, et al. · Melanoma Research · 14
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
2019 · Baptiste Louveau, Fanelie Jouenne, et al. · Cancers · 13
PDF
Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor
2017 · Baptiste Louveau, Jörg Tost, et al. · ESMO Open · 11
PDF
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
2025 · Jeremy Mo, Anne Zaremba, et al. · European Journal of Cancer · 10
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
2020 · Baptiste Louveau, Fanélie Jouenne, et al. · Targeted Oncology · 10
18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
2022 · Alexia Rivas, Julie Delyon, et al. · Cancers · 9
PDF
Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study
2021 · Lauriane Goldwirt, B. Louveau, et al. · Cancer Chemotherapy and Pharmacology · 8
1077MO PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study
2020 · J. Delyon, M. Resche-Rigon, et al. · Annals of Oncology · 8
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
2025 · Ikuan Sam, Nadine Benhamouda, et al. · EMBO Molecular Medicine · 7
Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.
2021 · Alison Margaret Weppler, Laetitia Da Meda, et al. · Journal of Clinical Oncology · 5
Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
2019 · Baptiste Louveau, Matthieu Resche-Rigon, et al. · Journal of Clinical Oncology · 5
A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).
2018 · Julie Delyon, Raphael Porcher, et al. · Journal of Clinical Oncology · 4
MelBase, constitution et suivi d’une cohorte nationale de patients atteints de mélanome stade III inopérable ou stade IV avec collection d’une base de données clinico-biologiques
2014 · C. Allayous, L. Da Meda, et al. · Annales de Dermatologie et de Vénéréologie · 4
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France
2026 · Jean-Yves Blay, Vincent Thevenet, et al. · EClinicalMedicine · 3
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based study
2025 · Jessica S.W. Borgers, Douglas B. Johnson, et al. · EClinicalMedicine · 3
Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients
2024 · Chloé Grolleau, Anouk Walter-Petrich, et al. · British Journal of Dermatology · 3
Works count: 69
Citation count: 542
H-index: 11
I10-index: 14
Year
Topic
Type